Document is current
Any future updates will be listed below
-
Authors
Miguel, Verónica https://orcid.org/0000-0001-9863-0710
Shaw, Isaac W. https://orcid.org/0000-0002-5628-0318
Kramann, Rafael https://orcid.org/0000-0003-4048-6351
- License Information
-
More Information
Article History
Accepted: 15 August 2024
First Online: 17 September 2024
Competing interests
: R.K. is founder and shareholder of Sequantrix GmbH, has grants from Travere Therapeutics, Galapagos, Chugai, AskBio and Novo Nordisk, and is a consultant for Bayer, Pfizer, Novo Nordisk, Hybridize Therapeutics and Gruenenthal. The other authors declare no competing interests.
